Time in Bed Restriction for Amyloidosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Amyloidosis+4 MoreTime in Bed Restriction - Behavioral
Eligibility
65 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial will explore whether better sleep can help mitigate the effects of Alzheimer's disease.

Eligible Conditions
  • Mild Cognitive Impairment
  • Sleep
  • Amyloidosis
  • Alzheimer's Disease
  • Cognitive Impairment

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Trazodone First
1
RAPA (rapamycin) treatment group
1
Dasatinib + Quercetin

Study Objectives

6 Primary · 10 Secondary · Reporting Duration: Baseline

Baseline
Amyloid positivity status
Apolipoprotein (ApoE) e4 allele carrier status
Clinical insomnia status
Cognitive status based on neuropsychological adjudication
Baseline and 4 weeks
Change in mean Plasma amyloid-beta 1-42
Mean change in Hippocampal Activation
Mean change in Sleep Efficiency
Mean change in accuracy on executive function tasks
Mean change in delta activity during sleep
Mean change in medial temporal-Hippocampal Connectivity
Mean change in response time on executive function tasks
Mean change in slow-oscillation activity assessed with electroencephalography
Mean percent signal change in medial prefrontal activation
Medial prefrontal-Hippocampal Connectivity
Overnight memory retention on the AB paired associate task, preclinical Alzheimer's cognitive composite score
mean change in plasma amyloid-beta composite score

Trial Safety

Safety Progress

1 of 3

Similar Trials

2
Trazodone First
2
RAPA (rapamycin) treatment group
2
Dasatinib + Quercetin

Trial Design

2 Treatment Groups

Control
1 of 2
Time in Bed Restriction
1 of 2

Active Control

Experimental Treatment

116 Total Participants · 2 Treatment Groups

Primary Treatment: Time in Bed Restriction · No Placebo Group · N/A

Time in Bed RestrictionExperimental Group · 2 Interventions: Time in Bed Restriction, Sleep Schedule · Intervention Types: Behavioral, Behavioral
Control
Behavioral
ActiveComparator Group · 1 Intervention: Sleep Schedule · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,617 Previous Clinical Trials
16,295,326 Total Patients Enrolled
1 Trials studying Amyloidosis
82 Patients Enrolled for Amyloidosis
National Institute on Aging (NIA)NIH
1,413 Previous Clinical Trials
3,484,100 Total Patients Enrolled
5 Trials studying Amyloidosis
2,301 Patients Enrolled for Amyloidosis

Eligibility Criteria

Age 65 - 85 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have normal or corrected-to-normal visual and auditory acuity.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top